> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rocket Pharmaceuticals Stock Falls 3% After Earnings — Commercial Preparations Push Administrative Costs Higher
- URL: https://www.bullished.co/rocket-pharmaceuticals-stock-falls-3-after-earnings-commercial-preparations-push-1b74854f/
- Published: 2026-11-13T15:43:49.000Z
- Updated: 2026-11-13T15:43:49.000Z
- Description: Research costs fell, but Rocket posted a $49.2 million quarterly loss as it prepared for commercial patient treatment.
- Author: Matteo Parrino
- Tags: Markets, RCKT, Industry: Healthcare

[Rocket Pharmaceuticals](https://www.bullished.co/tag/rckt/), which develops gene therapies for rare, often fatal diseases, fell 2.9% to $2.32 in Friday trading, as of 10:41 AM ET, losing $8 million in market value. The decline followed Thursday's earnings update, with a quarterly [net loss](https://www.sec.gov/Archives/edgar/data/1281895/000119312526458320/rckt-20260930.htm?ref=bullished.co) of $49.2 million as the company prepared for commercial patient treatment.

## Commercial Costs Rise, Research Costs Fall

Compared with the $18.4 million recorded a year earlier, Rocket's latest administrative expenses were higher at $19.8 million. The company attributed most of the increase to commercial preparations and obligations after marketing.

Against a year-earlier total of $34.1 million, [research spending declined](https://www.businesswire.com/news/home/20261112164218/en/Rocket-Pharmaceuticals-Reports-Third-Quarter-2026-Financial-Results-and-Highlights-Recent-Progress?ref=bullished.co) to $31.2 million. Rocket attributed the decline mainly to lower manufacturing costs and employee compensation.

Rocket said in Thursday's [earnings update](https://www.sec.gov/Archives/edgar/data/0001281895/000114036126043434/ef20085455%5F8k.htm?ref=bullished.co) that its cash and investments should fund planned operations through a period of clinical development and preparations for commercialization.

## Kresladi Moves Toward Patient Treatment

Kresladi became commercially ready earlier in October, and treatment centers were activated to bring patients onboard. The therapy addresses leukocyte adhesion deficiency-I, a rare immune disorder.

Rocket's gene therapies use modified viruses to put a functioning gene copy into patients' cells. Its principal development focus is rare heart disease, including Danon disease, a form of arrhythmogenic cardiomyopathy and a form of dilated cardiomyopathy.

Rocket arranged a credit facility of [up to $150 million](https://www.businesswire.com/news/home/20261112164218/en/Rocket-Pharmaceuticals-Reports-Third-Quarter-2026-Financial-Results-and-Highlights-Recent-Progress?ref=bullished.co) with Hercules Capital, the lender supporting its cardiovascular programs. The company produces clinical supply at its 103,720-square-foot facility in Cranbury, New Jersey.

Rocket has paused its Fanconi anemia and pyruvate kinase deficiency programs and is seeking partners for them.

## A Decline On A Difficult Year

Rocket shares were down 32% year to date at Thursday's close, compared with an 11% gain for the S&P 500\. In Friday trading, the stock was on pace for its largest one-day decline since Thursday, with a total market value of about $255 million.

The Danon disease trial remains a development priority. Rocket CEO Gaurav Shah said, "our priority is to complete dosing by mid-2027."

Rocket expects results from its Danon disease trial in mid-2028.

### Sources

- [Rocket Pharmaceuticals: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/rocket-pharmaceuticals-q3-earnings-snapshot/616-21abaa10-82db-4c99-8e33-37e1fbdd99dc?ref=bullished.co) — Associated Press
- [Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress](https://www.businesswire.com/news/home/20261112164218/en/Rocket-Pharmaceuticals-Reports-Third-Quarter-2026-Financial-Results-and-Highlights-Recent-Progress?ref=bullished.co) — businesswire.com
- [The company's filing (Rocket Pharmaceuticals)](https://www.sec.gov/Archives/edgar/data/0001281895/000114036126043434/ef20085455%5F8k.htm?ref=bullished.co) — SEC filing
- [Rocket Pharmaceuticals — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1281895/000119312526458320/rckt-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Rocket Pharmaceuticals

- [Rocket Pharmaceuticals Expects $279.4 Million To Carry Operations Past Planned Danon Trial Readout](https://www.bullished.co/rocket-pharmaceuticals-expects-279-4-million-to-carry-operations-past-planned-danon-trial-e3e5f5b7/)
- [Rocket Pharmaceuticals Has Only $35 Million Of A $150 Million Hercules Loan In Hand](https://www.bullished.co/rocket-pharmaceuticals-has-only-35-million-of-a-150-million-hercules-loan-in-hand-a7a945af/)

[All Rocket Pharmaceuticals (RCKT) coverage →](https://www.bullished.co/tag/rckt/)